Siu LL[Author] - Search Results

Year	Number of Results
1995	1
1996	1
1997	4
1998	8
1999	1
2000	7
2001	5
2002	11
2003	11
2004	7
2005	15
2006	14
2007	18
2008	19
2009	13
2010	16
2011	15
2012	19
2013	20
2014	25
2015	22
2016	17
2017	27
2018	20
2019	30
2020	26
2021	12

1

Small molecules, big impact: 20 years of targeted therapy in oncology.

Bedard PL, Hyman DM, Davids MS, Siu LL. Bedard PL, et al. Among authors: siu ll. Lancet. 2020 Mar 28;395(10229):1078-1088. doi: 10.1016/S0140-6736(20)30164-1. Lancet. 2020. PMID: 32222192 Review.

2

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.

Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Khoja L, et al. Among authors: siu ll. Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286. Ann Oncol. 2017. PMID: 28945858 Free article. Review.

3

How liquid biopsies can change clinical practice in oncology.

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. Siravegna G, et al. Among authors: siu ll. Ann Oncol. 2019 Oct 1;30(10):1580-1590. doi: 10.1093/annonc/mdz227. Ann Oncol. 2019. PMID: 31373349 Free article. Review.

4

Dose escalation methods in phase I cancer clinical trials.

Le Tourneau C, Lee JJ, Siu LL. Le Tourneau C, et al. Among authors: siu ll. J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. J Natl Cancer Inst. 2009. PMID: 19436029 Free PMC article. Review.

5

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.

Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, Siu LL, Chartash E, Aboshady H, Jain L. Lala M, et al. Among authors: siu ll. Eur J Cancer. 2020 May;131:68-75. doi: 10.1016/j.ejca.2020.02.016. Epub 2020 Apr 15. Eur J Cancer. 2020. PMID: 32305010

6

Molecular profiling for precision cancer therapies.

Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Malone ER, et al. Among authors: siu ll. Genome Med. 2020 Jan 14;12(1):8. doi: 10.1186/s13073-019-0703-1. Genome Med. 2020. PMID: 31937368 Free PMC article. Review.

7

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.

Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, Siu LL. Oliva M, et al. Among authors: siu ll. Ann Oncol. 2019 Jan 1;30(1):57-67. doi: 10.1093/annonc/mdy507. Ann Oncol. 2019. PMID: 30462163 Free PMC article. Review.

8

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Siu LL, et al. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. JAMA Oncol. 2019. PMID: 30383184 Free PMC article. Clinical Trial.

9

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH Jr, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Hellmann MD, et al. Among authors: siu ll. Ann Oncol. 2019 Jul 1;30(7):1134-1142. doi: 10.1093/annonc/mdz113. Ann Oncol. 2019. PMID: 30918950 Free PMC article. Clinical Trial.

10

Tumour heterogeneity in the clinic.

Bedard PL, Hansen AR, Ratain MJ, Siu LL. Bedard PL, et al. Among authors: siu ll. Nature. 2013 Sep 19;501(7467):355-64. doi: 10.1038/nature12627. Nature. 2013. PMID: 24048068 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results